Richard J. Benjamin Sells 9,890 Shares of Cerus Co. (CERS) Stock

Share on StockTwits

Cerus Co. (NASDAQ:CERS) insider Richard J. Benjamin sold 9,890 shares of the company’s stock in a transaction on Wednesday, March 13th. The shares were sold at an average price of $5.96, for a total value of $58,944.40. Following the completion of the transaction, the insider now directly owns 3,000 shares in the company, valued at $17,880. The sale was disclosed in a filing with the SEC, which is available through this link.

NASDAQ CERS traded up $0.11 on Friday, reaching $6.28. The stock had a trading volume of 503,158 shares, compared to its average volume of 744,396. The company has a debt-to-equity ratio of 0.26, a current ratio of 2.79 and a quick ratio of 2.53. Cerus Co. has a 1-year low of $4.70 and a 1-year high of $8.05. The firm has a market cap of $855.96 million, a price-to-earnings ratio of -14.26 and a beta of 1.44.

Cerus (NASDAQ:CERS) last issued its quarterly earnings data on Tuesday, February 26th. The biotechnology company reported ($0.12) EPS for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.01). The firm had revenue of $16.50 million during the quarter, compared to analyst estimates of $18.74 million. Cerus had a negative net margin of 84.15% and a negative return on equity of 65.35%. The business’s quarterly revenue was up 1.9% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.10) earnings per share. On average, equities analysts anticipate that Cerus Co. will post -0.42 earnings per share for the current fiscal year.

A number of research analysts have commented on the company. BidaskClub lowered Cerus from a “buy” rating to a “hold” rating in a report on Friday, March 1st. Zacks Investment Research lowered Cerus from a “buy” rating to a “hold” rating in a report on Monday, March 4th. ValuEngine raised Cerus from a “buy” rating to a “strong-buy” rating in a report on Monday, February 4th. Finally, Cantor Fitzgerald reaffirmed a “buy” rating and issued a $9.00 price objective on shares of Cerus in a report on Tuesday, December 18th. Three equities research analysts have rated the stock with a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the stock. Cerus has a consensus rating of “Buy” and a consensus price target of $8.50.

Large investors have recently added to or reduced their stakes in the company. Two Sigma Securities LLC bought a new stake in shares of Cerus during the 4th quarter valued at $55,000. Raymond James Trust N.A. bought a new stake in shares of Cerus during the 4th quarter valued at $71,000. Mackenzie Financial Corp bought a new stake in shares of Cerus during the 3rd quarter valued at $119,000. Shufro Rose & Co. LLC lifted its position in shares of Cerus by 13.3% during the 4th quarter. Shufro Rose & Co. LLC now owns 17,000 shares of the biotechnology company’s stock valued at $86,000 after acquiring an additional 2,000 shares during the period. Finally, Amalgamated Bank bought a new stake in shares of Cerus during the 4th quarter valued at $99,000. Hedge funds and other institutional investors own 65.15% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Richard J. Benjamin Sells 9,890 Shares of Cerus Co. (CERS) Stock” was originally published by Zolmax and is the property of of Zolmax. If you are reading this piece on another website, it was illegally stolen and republished in violation of US & international copyright & trademark laws. The legal version of this piece can be read at https://zolmax.com/investing/richard-j-benjamin-sells-9890-shares-of-cerus-co-cers-stock/2964997.html.

About Cerus

Cerus Corporation, a biomedical products company, focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.

Featured Story: What factors cause inflation to rise?

Insider Buying and Selling by Quarter for Cerus (NASDAQ:CERS)

Receive News & Ratings for Cerus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerus and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

$86.75 Million in Sales Expected for PTC Therapeutics, Inc.  This Quarter
$86.75 Million in Sales Expected for PTC Therapeutics, Inc. This Quarter
Q4 2020 Earnings Forecast for Childrens Place Inc  Issued By Wedbush
Q4 2020 Earnings Forecast for Childrens Place Inc Issued By Wedbush
3D Systems  Downgraded to D at TheStreet
3D Systems Downgraded to D at TheStreet
Legg Mason Inc Forecasted to Earn FY2020 Earnings of $2.70 Per Share
Legg Mason Inc Forecasted to Earn FY2020 Earnings of $2.70 Per Share
Q2 2020 EPS Estimates for Macy’s Inc  Lowered by Jefferies Financial Group
Q2 2020 EPS Estimates for Macy’s Inc Lowered by Jefferies Financial Group
National Bank Financial Analysts Give Nevada Copper  a C$0.75 Price Target
National Bank Financial Analysts Give Nevada Copper a C$0.75 Price Target


 
© 2006-2019 Zolmax.